Journal
JOURNAL OF NEUROVIROLOGY
Volume 27, Issue 2, Pages 302-324Publisher
SPRINGER
DOI: 10.1007/s13365-021-00956-2
Keywords
Human immunodeficiency virus; Neurocognitive; Neurotrophin; Therapy; Behavior; Neuroprotection
Categories
Funding
- NIH [R21 R21 NS086426, RO1 MH 063646]
Ask authors/readers for more resources
Neurotrophin-based therapies have the potential to stabilize and repair the nervous system in HIV-infected individuals. LM11A-31, a non-peptide ligand targeting the p75 neurotrophin receptor, showed strong neuroprotective effects in a natural infection model with chronically FIV-infected cats, preventing cognitive decline and neural dysfunction.
HIV rapidly infects the central nervous system (CNS) and establishes a persistent viral reservoir within microglia, perivascular macrophages and astrocytes. Inefficient control of CNS viral replication by antiretroviral therapy results in chronic inflammation and progressive cognitive decline in up to 50% of infected individuals with no effective treatment options. Neurotrophin based therapies have excellent potential to stabilize and repair the nervous system. A novel non-peptide ligand, LM11A-31, that targets the p75 neurotrophin receptor (p75(NTR)) has been identified as a small bioavailable molecule capable of strong neuroprotection with minimal side effects. To evaluate the neuroprotective effects of LM11A-31 in a natural infection model, we treated cats chronically infected with feline immunodeficiency virus (FIV) with 13 mg/kg LM11A-31 twice daily over a period of 10 weeks and assessed effects on cognitive functions, open field behaviors, activity, sensory thresholds, plasma FIV, cerebrospinal fluid (CSF) FIV, peripheral blood mononuclear cell provirus, CD4 and CD8 cell counts and general physiology. Between 12 and 18 months post-inoculation, cats began to show signs of neural dysfunction in T maze testing and novel object recognition, which were prevented by LM11A-31 treatment. Anxiety-like behavior was reduced in the open field and no changes were seen in sensory thresholds. Systemic FIV titers were unaffected but treated cats exhibited a log drop in CSF FIV titers. No significant adverse effects were observed under all conditions. The data indicate that LM11A-31 is likely to be a potent adjunctive treatment for the control of neurodegeneration in HIV infected individuals.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available